US Bancorp
TSHA icon

US Bancorp’s Taysha Gene Therapies TSHA Stock Holding History

US Bancorp’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.84K Buy
1,152
+145
+14% +$858 ﹤0.01% 3525
2026
Q1 		$4.5K Buy
1,007
+95
+10% +$442 ﹤0.01% 3604
2025
Q4 		$5.02K Hold
912
– – ﹤0.01% 3528
2025
Q3 		$2.98K Sell
912
-63
-6% -$178 ﹤0.01% 3688
2025
Q2 		$2.25K Buy
975
+44
+5% +$96 ﹤0.01% 3848
2025
Q1 		$1.29K Buy
931
+203
+28% +$340 ﹤0.01% 3946
2024
Q4 		$1.26K Sell
728
-132
-15% -$274 ﹤0.01% 3929
2024
Q3 		$1.73K Sell
860
-15,217
-95% -$33.4K ﹤0.01% 3820
2024
Q2 		$36K Sell
16,077
-1,561
-9% -$4.54K ﹤0.01% 2823
2024
Q1 		$50.6K Buy
+17,638
New +$36.8K ﹤0.01% 2685
2022
Q1 		– Sell
-524
Closed -$6K – 4201
2021
Q4 		$6K Buy
+524
New +$7.9K ﹤0.01% 3604

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

US Bancorp's TSHA Position: Q2 2026 in Review

US Bancorp increased its Taysha Gene Therapies (TSHA) stake by 14% in Q2 2026, buying an estimated $858 and bringing the position to 1,152 shares worth $7.84K. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

US Bancorp first reported a position in TSHA in Q4 2021 and has held it in 11 quarters since. The position peaked at $50.6K in Q1 2024. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • US Bancorp held 1,152 shares of Taysha Gene Therapies worth $7.84K as of Q2 2026.
  • US Bancorp bought 145 Taysha Gene Therapies shares in Q2 2026, an estimated $858.
  • Taysha Gene Therapies made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3525 holding.
  • US Bancorp first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 11 quarters since.
  • US Bancorp's Taysha Gene Therapies position peaked at $50.6K in Q1 2024.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.